Israeli Medical Advances Receive FDA Approval

January 8, 2006

“Lumenis has provided the ophthalmic industry with innovative technology since 1970, when we introduced the world’s first laser photocoagulator,” said Lumenis President and CEO Avner Raz. “Worldwide, estimates suggest over 30 million people suffer from these conditions; and as the population ages, these numbers are expected to climb. With the addition of our Novus 3000, we once again demonstrate our commitment to helping patients and their ophthalmologists protect and preserve eyesight.”

For further information, please contact Lumenis Ltd., P.O. Box 240, Yokneam 20692, Israel; Tel: 972-4-959-9000; Fax: 972-4-959-9050; Web site: www.lumenis.com

Galil Medical, another Israeli company, has announced that its CryoHit product family has received FDA approval. The devices are critical to the treatment of breast fibroadenoma––the most common benign breast tumor in women under 40, affecting millions of women worldwide.

These tumors have traditionally been removed through a surgical excision under local anesthesia in an operating theater. With Galil’s minimally invasive new product line, the procedure can be performed at a local clinic, resulting in short recovery and much less of a chance of scarring. The procedure involves the application of sub-zero temperatures to freeze the tumors, using needles capable of creating ice-balls of diverse sizes and shapes to match the shape of the tumor exactly. Galil’s cryotherapy technology is already widely used worldwide for the treatment of prostate, kidney, and liver cancer.

For further information, please contact Galil Medical, P.O. Box 224, Sha’ar Yokneam, Tabor 1, Yokneam 20692, Israel; Tel: 972-4-959-1080; Fax: 972-4-959-1077; E-mail: info@galil-medical.co.il; Web site: www.galilmedical.com

Photo Credit: